Seattle, WA / ACCESSWIRE / May 23, 2014 / TapImmune Inc. (OTCQB: TPIV), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease is pleased to update shareholders and investors on recent and upcoming corporate events.
The company will be presenting at three conferences in New York starting with an invitation only broker meeting on May 27th, followed by the SeeThrough Equity Annual Microcap Conference on 28th where the company will present at 2pm and finally the annual Marcum Microcap Conference on the 29th, presenting at 4pm. All presentations will discuss TapImmune's unique position in the exciting immunotherapy space and clinical progress in both the Her2neu Breast cancer trial and the Folate Receptor Alpha Breast and Ovarian Cancer trial being conducted at Mayo Clinic in Rochester MN.
In addition, TapImmune is pleased to announce significant progress in using its technologies for the treatment of viral disease. Specific peptides expressed in TapImmune's exciting Polystart(tm) technology resulted in the killing of targeted human cells thus providing the first proof of concept that this approach works and could potentially be more widely applied in the development of urgently needed vaccines for emerging diseases like MERS and others that require immediate responses. Small animal studies with a peptide based vaccine for prevention of smallpox have been very encouraging and indicate commercial product potential. The studies completed at The Mayo Clinic in Rochester MN included a set of novel peptides with TapImmunes proprietary antigen presenting platforms to augment vaccine efficacy. TapImmune believes that these platforms could substantially improve many vaccines in development and currently on the market.
TapImmune's CEO Glynn Wilson commented, "We are extremely pleased with the progress we have made this year and the Company's fundamentals have never been stronger. Our preclinical and clinical programs are progressing as we hoped and we are expecting to move all programs forward to their respective next phases." He further stated, "The positive momentum on the clinical side of the business should translate into significant value drivers for our shareholders in both the short and long terms."
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company's vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at www.tapimmune.com for details.
Forward-Looking Statement Disclaimer: This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements
Glynn Wilson, PH.D.
Chairman & CEO
SOURCE: TapImmune Inc.